Shire to Buy Rival Drug Maker Dyax for $5.9B

The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
Matthew HellerNovember 2, 2015

Shire Plc said Monday it has agreed to acquire biotech company Dyax for at least $5.9 billion, continuing an acquisition spree aimed at diversifying the Irish drug maker away from its historically dominant hyperactivity business.

Shire’s $37.30 offer for each Dyax share is a 35% premium over the stock’s Friday closing price. Dyax investors will get an additional $4 a share, or $646 million, if its DX-2930 experimental drug for hereditary angioedema (HAE), a rare and potentially life-threatening disease that causes swelling, receives regulatory approval by the end of 2019.

According to Bloomberg, the deal “allows Shire to take over a drug that posed a serious threat to Cinryze, its fastest growing medicine, which prevents HAE attacks.” DX-2930 will generate annual sales of as much as $2 billion globally and have patent protection and other exclusivity pacts beyond 2030, the companies said.

CFO Insights on Inflation, Workforce Challenges, and Future Plans 

CFO Insights on Inflation, Workforce Challenges, and Future Plans 

Download our 2022 survey report for a high-level view of finance team projections and strategies, directly from our executive readers.

“DX-2930 is a strategic fit within our HAE domain expertise, and we are well-positioned to advance the development, registration, and commercialization of DX-2930 for the benefit of HAE patients,” Shire Chief Executive Flemming Ørnskov said.

Dyax share’s were up more than 28%, at $35.37, in trading Monday.

As The Wall Street Journal reports, Ørnskov has presided over a string of small-to-midsize acquisitions since becoming CEO two-and-a-half years ago. In Shire’s largest deal to date, it acquired in January to acquire NPS Pharmaceuticals, a maker of treatments for rare diseases, for $5.2 billion.

Shire has also been locked in a three-month battle to acquire rare-disease rival Baxalta, which rejected a $30 billion offer. “Even with [the Dyax] transaction, we will continue to have the financial firepower to pursue other value-added strategic acquisitions, including Baxalta,” Ørnskov said.

Shire’s existing HAE treatments Firazyr and Cinryze are two of its fast-growing products, with combined sales approaching $1 billion. According to The Journal, DX-2930 was “one of the biggest competitive threats to Shire’s hereditary angioedema franchise, because it is significantly more convenient to take than Shire’s Cinryze.”

DX-2930 is taken once every two weeks by simple injection, whereas Cinryze is taken twice a week intravenously.

4 Powerful Communication Strategies for Your Next Board Meeting